We would love to hear your thoughts about our site and services, please take our survey here.
Found it ......
Worth a watch ODX Colin King presentation from October 20 around production capacity then an interesting bit on the target line for bringing the Mologic antigen test into production, the slide refers to a saliva test but CK never mentions saliva and the deadline for the mologic test also appear to have slipped ....
https://www.investormeetcompany.com/investor/meeting/trading-update-investor-presentation-1
And Breathe.....
Happy Friday to all LTH - Well done.
Saliva based antigen test in Italy.....Mologic even gets a mention.
https://innovationorigins.com/in-new-twist-quick-saliva-test-can-help-fight-against-covid-19/
No and Yes.
Looking back there have been numerous details about similar routes through the process and the language around the end goal has been very similar...
Liverpool School of Tropical Medicine....
Saliva based test......
Links to GAD
Low to medium income country’s
Mologic and Avacta go back to 2016
Too many pages open...Found it.
https://mologic.co.uk/mologic-covid-19-testing-at-heathrow-airport/
Hopefully Al has his eye on this prize $500million
In addition, Mologic’s COVID-19 Rapid Antigen Test has been invited to take part in the US National Institutes of Health (NIH) RADx initiative that will fast-track development, manufacture, and regulatory submissions.
RADxSM Tech
The RADx Tech initiative aims to speed the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improve clinical laboratory tests, that can directly detect the virus.
Budget: $500 Million
Phases of the RADx Initiative
The RADx Tech initiative aims to speed the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improve clinical laboratory tests, that can directly detect the virus.
RADx Tech has expanded the Point-of-Care Technologies Research Network(link is external) (POCTRN) established several years ago by NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB).
The network is using a flexible, rapid process to infuse funding and enhance technology designs at key stages of development, with expertise from technology innovators, clinical testing, regulatory affairs, entrepreneurs, and business leaders.
Scientists and inventors with a rapid testing technology compete in a national “shark tank”-type COVID-19 testing challenge for a share of up to $500 million over all phases of development. The technologies go through a highly competitive, rapid three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19. Finalists are then matched with technical, business, and manufacturing experts to increase the odds of success.
If certain selected technologies are already relatively far along in development, they can be advanced immediately to the appropriate step in the commercialization process.
Starting in summer 2020, this two-year effort will award funding on a rolling basis.
More and More curious.....
On the 29th August Mologic stated it had a test as part of a three test trail at Heathrow Airport
"Mologic has put forward a lateral flow solution which uses a saliva sample on a test device, which provides a visually read result in 10 minutes."
Also take a read of this from 5th january 2021
https://www.mpo-mag.com/content-microsite/mpo_covid-19/2021-01-05/mologic-covid-19-rapid-antigen-test-receives-ce-mark-approval
Within a consortium ??
Prof. Sanjeev Krishna, St George's University of London, concluded, “The urgency for affordable diagnostics that are quality assured has been highlighted by the need to free people from quarantine and enable travel. Working within a consortium with Mologic and academic partners has been one of the most effective ways to develop such tests.”
Anyone remember mologic having a saliva based test on trial at Heathrow ????
Ok so on the 24th December
They said
"Preliminary results show 92% sensitivity and 100% specificity, compared with RT-PCR"
"from January 2021. Dossiers will be prepared for submission to the US FDA and WHO at that same time."
" To guarantee access to the rapid test in low- and middle-income countries, the COVID-19 Rapid Antigen Test will be manufactured and made available by Global Access Diagnostics (GAD), at cost of production and distributed through commercialisation partners"
"In addition, Mologic’s COVID-19 Rapid Antigen Test has been invited to take part in the US National Institutes of Health (NIH) RADx initiative that will fast-track development, manufacture, and regulatory submissions"
On the 8th Feb our RNS said
"Partnership to accelerate CE marking of Avacta's SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries"
"The partnership also immediately provides Avacta with additional manufacturing capacity through Mologic and its partners including Global Access Diagnostics (GAD)"
"Clinical evaluation of the lateral flow test is currently being carried out at a hospital in mainland Europe and the Company will shortly initiate further clinical validation studies in the UK and abroad."
Got to be....
Its got to be us....
They said in Dec 20...
" To guarantee access to the rapid test in low- and middle-income countries, the COVID-19 Rapid Antigen Test will be manufactured and made available by Global Access Diagnostics (GAD), at cost of production and distributed through commercialisation partners."
Todays RNS...... We said
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, announces that it has entered into a commercial partnership with Mologic Ltd ("Mologic") to accelerate to market Avacta's AffiDX™ SARS-CoV-2 lateral flow rapid antigen test. Avacta will also support antigen testing in low and middle income countries[1] by providing access to Avacta's spike antigen test through Mologic.
The partnership also immediately provides Avacta with additional manufacturing capacity through Mologic and its partners including Global Access Diagnostics (GAD)
???????????
So was this our test or mologics test ????
https://mologic.co.uk/mologic-receives-ce-mark-approval-for-professional-use-covid-19-rapid-antigen-test/
Mologic seems to be the ODX Avacta link....
Anyone notice the almost identical infection curve dates between the UK variant and the S African ?
Also had a meeting today about in house testing (Innova )and there was an agreement that people on anti-coagulants such as warfarin, people with nasal polyps and people subject to nose bleeds would be exempt .